During the present reporting period, our research in this area was limited due to severe reductions in available research resources. Nevertheless, we carried out one collaborative research project dealing with ghrelin and the ghrelin receptor. Ghrelin, a stomach-derived hormone implicated in numerous behaviors including feeding, reward, stress, and addictive behaviors, acts by binding to the growth hormone secretagogue receptor (GHSR). In this collaborative research project, we developed, verified, and carried out initial characterization of a novel GHSR knockout (KO) Wistar rat model created with CRISPR genome editing. Specifically, using CRISPR/Cas9, we developed a GHSR KO in a Wistar background. Loss of GHSR mRNA expression was histologically verified using RNAscope in wild-type (WT) and KO rats. We tested the effects of intraperitoneal acyl-ghrelin administration on food consumption and plasma growth hormone (GH) concentrations in WT and KO rats. We also analyzed locomotion, food consumption, and body fat composition in these animals. Body weight was monitored from early development to adulthood. The RNAscope analysis revealed an abundance of GHSR mRNA expression in the hypothalamus, midbrain, and hippocampus in WTs, and no observed probe binding in KOs. Ghrelin administration significantly increased plasma GH levels and food consumption in WT rats but not in KO rats. KO rats consumed significantly less food overall at basal conditions and weighed significantly less compared with WT rats throughout development. Compared with WT rats, KO rats presented significantly higher concentrations of brown adipose tissue. We verified GHSR deletion in our KO model using histological, physiological, neuroendocrinological, and behavioral measures. Our findings indicate that GHSR deletion in rats is not only associated with a lack of response to ghrelin, but also associated with decreases in daily food consumption and body growth, and increases in brown adipose tissue. This GHSR KO Wistar rat model provides a novel tool for studying the role of the ghrelin system in obesity and in a wide range of medical and neuropsychiatric disorders - including, potentially, drug addiction.

Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2018
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
Zip Code
Zallar, L J; Tunstall, B J; Richie, C T et al. (2018) Development and initial characterization of a novel ghrelin receptor CRISPR/Cas9 knockout wistar rat model. Int J Obes (Lond) :
Xue, Xue; Yang, Jing-Yu; He, Yi et al. (2016) Aggregated single-walled carbon nanotubes attenuate the behavioural and neurochemical effects of methamphetamine in mice. Nat Nanotechnol 11:613-20
Blum, Kenneth; Thanos, Peter K; Oscar-Berman, Marlene et al. (2015) Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. J Reward Defic Syndr 1:95-104
Wang, Xiao-Fei; Bi, Guo-Hua; He, Yi et al. (2015) R-modafinil attenuates nicotine-taking and nicotine-seeking behavior in alcohol-preferring rats. Neuropsychopharmacology 40:1762-71
Zhang, Hai-Ying; Bi, Guo-Hua; Li, Xia et al. (2015) Species differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and rats. Neuropsychopharmacology 40:1037-51
Blum, Kenneth; Gardner, Eliot; Oscar-Berman, Marlene et al. (2012) ""Liking"" and ""wanting"" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. Curr Pharm Des 18:113-8
Xi, Zheng-Xiong; Peng, Xiao-Qing; Li, Xia et al. (2011) Brain cannabinoid CB? receptors modulate cocaine's actions in mice. Nat Neurosci 14:1160-6
Gardner, Eliot L (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30:22-60
Xi, Zheng-Xiong (2010) Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. Drug Healthc Patient Saf 2010:39-48
Xi, Zheng-xiong; Spiller, Krista; Gardner, Eliot L (2009) Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin 30:723-39

Showing the most recent 10 out of 13 publications